NCT00193362已完成3 期
Phase III Randomized Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine as First-Line Chemotherapy for Stage IIIB and IV Non-Small Cell Lung Cancer
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 200
- 主要终点
- Overall survival.
研究概览
简要总结
The purpose of this study is to compare the effectiveness of the three-drug combination paclitaxel, carboplatin, and gemcitabine to the two-drug combination gemcitabine and vinorelbine in patients with advanced Non-Small Cell Lung Cancer
详细描述
Upon determination of eligibility, patients will be randomly assigned to one of two treatment arms:
- Paclitaxel + Carboplatin + Gemcitabine
- Gemcitabine + Vinorelbine
For ever 2 patients treated, 1 will receive treatment A (Paclitaxel + Carboplatin + Gemcitabine) and 1 will receive treatment B (Gemcitabine + Vinorelbine). The study is not blinded so both the patient and the doctor will know which treatment has been assigned.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be included in this study, you must meet the following criteria:
- •Non-small cell bronchogenic carcinoma
- •Newly diagnosed unresectable stage IIIB or stage IV disease
- •Patients with stage IIIB disease should be ineligible for combined therapy
- •Patients must have measurable lesion definable by X-ray or CT scan.
- •No prior antineoplastic chemotherapy for lung cancer prior to study entry
- •Age > 18 years
- •Able to perform activities of daily living with minimal assistance
- •Adequate bone marrow, liver and kidney function
- •Written informed consent must be obtained prior to study entry
- •Patients must be available for treatment and followup.
排除标准
- •You cannot participate in this study if any of the following apply to you:
- •Female patient pregnant or lactating
- •History of heart disease
- •Serious active infection at the time of treatment
- •Other serious underlying medical condition
- •Brain metastasis
- •Patients without measurable disease
- •Uncontrolled diabetes mellitus defined as random blood sugar > 250mg/dL
- •Dementia or significantly altered mental status
- •Significant peripheral neuropathy by history or physical examination.
- •Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
结局指标
主要结局
Overall survival.
次要结局
- Overall response rate
- Overall toxicity
- Time-to-progression
- Assess the quality of life
研究者
相似试验
Unknown
3 期
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity CancerStage IA Uterine Sarcoma AJCC v7Mixed Mesodermal (Mullerian) TumorStage IA Ovarian Cancer AJCC v6 and v7Stage IB Fallopian Tube Cancer AJCC v6 and v7Stage IC Ovarian Cancer AJCC v6 and v7Stage IIA Uterine Sarcoma AJCC v7Stage IIC Fallopian Tube Cancer AJCC v6 and v7Stage IIIA Ovarian Cancer AJCC v6 and v7Stage IIIB Uterine Sarcoma AJCC v7Stage IV Fallopian Tube Cancer AJCC v6 and v7Stage IVB Uterine Sarcoma AJCC v7Recurrent Primary Peritoneal CarcinomaStage IB Uterine Sarcoma AJCC v7Stage IC Fallopian Tube Cancer AJCC v6 and v7Stage II Ovarian Cancer AJCC v6 and v7Stage IIB Uterine Sarcoma AJCC v7Stage IIIC Primary Peritoneal Cancer AJCC v7Stage IV Ovarian Cancer AJCC v6 and v7Uterine CarcinosarcomaRecurrent Fallopian Tube CarcinomaStage I Ovarian Cancer AJCC v6 and v7Stage IB Ovarian Cancer AJCC v6 and v7Stage IIA Fallopian Tube Cancer AJCC v6 and v7Stage IIB Ovarian Cancer AJCC v6 and v7Stage IIIA Primary Peritoneal Cancer AJCC v7Stage IIIA Uterine Sarcoma AJCC v7Stage IIIC Ovarian Cancer AJCC v6 and v7Stage IIIC Uterine Sarcoma AJCC v7Stage IV Primary Peritoneal Cancer AJCC v7Stage IVA Uterine Sarcoma AJCC v7Ovarian CarcinosarcomaRecurrent Ovarian CarcinomaStage IA Fallopian Tube Cancer AJCC v6 and v7Stage IC Uterine Sarcoma AJCC v7Stage IIA Ovarian Cancer AJCC V6 and v7Stage IIB Fallopian Tube Cancer AJCC v6 and v7Stage IIC Ovarian Cancer AJCC v6 and v7Stage IIIA Fallopian Tube Cancer AJCC v7Stage IIIB Primary Peritoneal Cancer AJCC v7Stage IIIB Fallopian Tube Cancer AJCC v7Stage IIIB Ovarian Cancer AJCC v6 and v7Stage IIIC Fallopian Tube Cancer AJCC v7NCT00954174GOG Foundation637
终止
3 期
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung CancerRecurrent Lung AdenocarcinomaStage IV Squamous Cell Lung CarcinomaStage IV Lung AdenocarcinomaRecurrent Squamous Cell Lung CarcinomaRecurrent Large Cell Lung CarcinomaStage IV Large Cell Lung CarcinomaNCT00946712SWOG Cancer Research Network1,333
已完成
3 期
Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)Uterine Cervical NeoplasmsNCT00295789Haruhiko Fukuda253
进行中（未招募）
3 期
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerOvarian Low Grade Serous AdenocarcinomaPrimary Peritoneal Low Grade Serous AdenocarcinomaStage IV Primary Peritoneal Cancer AJCC v8Low Grade Fallopian Tube Serous AdenocarcinomaStage II Fallopian Tube Cancer AJCC v8Stage II Ovarian Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage IV Fallopian Tube Cancer AJCC v8Stage II Primary Peritoneal Cancer AJCC v8Stage III Fallopian Tube Cancer AJCC v8Stage III Primary Peritoneal Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8NCT04095364NRG Oncology450
已完成
3 期
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerStage IIIA Fallopian Tube CancerStage IIIA Ovarian CancerStage IIIA Primary Peritoneal CancerStage IIIB Fallopian Tube CancerStage IIIB Ovarian CancerStage IIIB Primary Peritoneal CancerStage IIIC Fallopian Tube CancerStage IIIC Ovarian CancerStage IIIC Primary Peritoneal CancerUndifferentiated Ovarian CarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Transitional Cell CarcinomaMalignant Ovarian Mixed Epithelial TumorOvarian Brenner TumorOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mucinous AdenocarcinomaOvarian Serous AdenocarcinomaOvarian Transitional Cell CarcinomaPrimary Peritoneal Serous AdenocarcinomaStage IV Fallopian Tube CancerStage IV Ovarian CancerStage IV Primary Peritoneal CancerUndifferentiated Fallopian Tube CarcinomaNCT00262847National Cancer Institute (NCI)1,873